Visible Genetics' HIV resistance testing software:
This article was originally published in Clinica
Visible Genetics has received US FDA 510(k) clearance to market its next-generation HIV resistance interpretation software for use with its TRUGENE HIV-1 genotyping test. The GuideLines 5.0 Rules software includes the latest data on HIV drug resistance, including information on the newly launched HIV drugs, tenofovir and lopinavir/ritonavir. The HIV virus is constantly evolving and it is critical that HIV resistance testing is conducted using technology that is both fully validated and up-to-date, says the Toronto, Canada firm.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.